EUVIMEDObjevte EUVIMED
Open access · CC BY 3.0

Assessment of the Effects of Zoledronic Acid Therapy on Bone Metabolic Indicators in Hormone-Resistant Prostate Cancer Patients with Bone Metastatasis

Abdullah Demirtas, Nurettin Sahin, Mehmet Caniklioglu, Mustafa Kula, Oguz Ekmekcioglu, Atila Tatlisen

ISRN Urology · 2011

DOI: 10.5402/2011/392014 ↗

At a glance

Journal article in ISRN Urology, 2011. Written by Abdullah Demirtas and 5 co-authors. Institution: Department of Urology, Erciyes University Faculty of Medicine, Kayseri, Turkey. Cited 1 times so far (Crossref); 18 references. The full text is freely available (open access, CC BY 3.0).

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

Purpose

Assessment of effects of zoledronic acid therapy on bone metabolic indicators in hormone-resistant prostate cancer patients with bone metastasis. Material and Methods . Hormone-resistant prostate cancer patients who were identified to have metastases in their bone scintigraphy were taken to trial group. Before administration of zoledronic acid, routine tests for serum calcium, total alkalen phosphates were studied. Sample sera for bone metabolic indicators BALP, PINP, and ICTP were collected. Bone pain was assessed via visual analogue scale and performance via Karnofsky performance scale. Four mg zoledronic acid was administered intravenously once a month.

Results

When serum levels of bone forming indicators PINP; BALP were compared before and after therapy, there were insignificant decreases (, , resp.). Serum levels of bone destruction indicator ICTP was compared, and there was a significant decrease after zoledronic acid therapy (). When performances of the patients were compared during therapy period, performances decreased significantly due to progress of illness (). All patients had ostalgia caused by bone metastases at various degrees. Significant decrease in pain scores was observed ().

Conclusion

Zoledronic acid therapy decreased bone destruction and was effective in palliation of pain in patient with bone metastasis. Using bone metabolic indicators during followup of zoledronic acid therapy might be useful.

Authors and institutions

  • Department of Urology, Erciyes University Faculty of Medicine, Kayseri, Turkey.

Cite

APA

Demirtas, A., Sahin, N., Caniklioglu, M., Kula, M., Ekmekcioglu, O., & Tatlisen, A. (2011). Assessment of the Effects of Zoledronic Acid Therapy on Bone Metabolic Indicators in Hormone-Resistant Prostate Cancer Patients with Bone Metastatasis. ISRN Urology. https://doi.org/10.5402/2011/392014

Vancouver

Demirtas A, Sahin N, Caniklioglu M, Kula M, Ekmekcioglu O, Tatlisen A. Assessment of the Effects of Zoledronic Acid Therapy on Bone Metabolic Indicators in Hormone-Resistant Prostate Cancer Patients with Bone Metastatasis. ISRN Urology. 2011. doi:10.5402/2011/392014

BibTeX
@article{Demirtas2011,
  author = {Demirtas, Abdullah and Sahin, Nurettin and Caniklioglu, Mehmet and Kula, Mustafa and Ekmekcioglu, Oguz and Tatlisen, Atila},
  title = {Assessment of the Effects of Zoledronic Acid Therapy on Bone Metabolic Indicators in Hormone-Resistant Prostate Cancer Patients with Bone Metastatasis},
  journal = {ISRN Urology},
  year = {2011},
  doi = {10.5402/2011/392014}
}
Start for free →